Evidence map›Paper›PMID 35283500›Full record

ArticleIndian journal of dermatology

Female Patient with Two Simultaneous Giants Facial Basal Cell Carcinomas Demonstrates a Positive Response to Vismodegib as a Monotherapy.

Sofia Theotokoglou, Dimitrios Sgouros, Konstantinos Theodoropoulos, Anna Syrmali, George Polyderas, Alexander C Katoulis

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sofia TheotokoglouSecond Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "ATTIKON" University Hospital, Athens, Greece.
Dimitrios SgourosSecond Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "ATTIKON" University Hospital, Athens, Greece.
Konstantinos TheodoropoulosSecond Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "ATTIKON" University Hospital, Athens, Greece.
Anna SyrmaliSecond Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "ATTIKON" University Hospital, Athens, Greece.
George PolyderasSecond Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "ATTIKON" University Hospital, Athens, Greece.
Alexander C KatoulisSecond Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "ATTIKON" University Hospital, Athens, Greece.
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Basal cell carcinoma (BCC) is the most frequent histological type of cancer in the world and accounts for approximately 80% of all skin cancers. In the majority of cases, they are slow-growing, low metastatic potential tumors, easy to cure by surgical or nonsurgical procedures. Giant BCC (GBCC) is a rare variant of BCC and according to the American Joint Committee on Cancer, this includes lesions with a diameter larger than 5 cm. GBCC's incidence has been reported to be less than 1%, and it displays a more aggressive behavior with both local invasion and higher metastatic potential. Archodaki

Indexed as

Basal cell carcinomagiant basal cell carcinomamonotherapyvismodegib

Identifiers

PMID35283500
PMCPMC8906300
OpenAlexW4220714705

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.